United States: Is Your Smart Phone An FDA-Regulated Medical Device? - FDA Announces Plans To Regulate "Mobile Medical Applications"

Last Updated: August 9 2011
Article by Jonathan Berman

An enormous number of software applications have been developed for use on handheld computers such as smart phones, tablet computers, and personal digital assistants. Some of these applications are marketed as suitable for diagnosing or treating disease, or for controlling other machines that are used for these purposes.

On July 21, 2011, the U.S. Food and Drug Administration issued a "draft guidance" discussing how it intends to regulate "mobile medical apps."1 The FDA views handheld computers loaded with these apps to be medical "devices" subject to extensive FDA regulation. The FDA's draft guidance sets out its current thinking regarding when apps will trigger regulatory oversight, and how the FDA intends to enforce its regulations.

Since the FDA will be exercising its authority over industries that may be unaccustomed to FDA regulation, the affected companies are in danger of inadvertent regulatory violations. The FDA is focusing primarily on companies that write or design software for medical apps. But, depending on the circumstances, companies that manufacture or distribute the hardware also face regulatory risk. All companies in any way involved with handheld computers or their apps would be well advised to consult with regulatory counsel to determine how they may be affected by the FDA's device regulations.

The FDA is actively seeking input into its policies. Companies that want a say in the FDA's enforcement practices should promptly submit comments to the new "draft guidance."

Medical Devices and the FDA

The FDA has long had authority to regulate medical "devices," a term that encompasses instruments, machines, implants, and other articles "intended for use in the diagnosis of disease ... or in the cure, mitigation, treatment, or prevention of disease ...." FD&C Act, § 201(h). Regulated "devices" range from extremely simple items, such as dental floss and stethoscopes,2 to pacemakers3 and highly sophisticated medical equipment.

Manufacturers and others involved in the marketing of medical devices are subject to a raft of regulatory requirements. See generally 21 C.F.R. Chapter 1, Subchapter H. Many devices cannot be marketed without prior permission from the FDA. FD&C Act, § 510(k); 21 C.F.R. § 807.100(a). Novel or potentially dangerous devices may be subject to a rigorous premarket approval process requiring expensive and time-consuming clinical trials. See FD&C Act, § 515; 21 C.F.R. Part 814.

Other regulations mandate registering manufacturing establishments, ensuring proper labeling, reporting adverse events, malfunctions, and corrections, and (depending on the device at issue), manufacturing in accordance with "quality system" and "current good manufacturing process" regulations, tracking the devices after they are sold, and performing postmarket surveillance to collect data on the device's safety and efficacy.4

Mobile Medical Apps

The popularity of smart phones and other handheld computers has resulted in a profusion of software applications designed to run on the handheld computers. Some of these "apps" are designed for medical purposes. The FDA's recent draft guidance lists 34 types of apps that the FDA views as "mobile medical apps," including apps that permit the user to analyze medical data, screen patients for blood transfusions, control other medical devices, etc. According to the new draft guidance, a handheld computer loaded with such apps is a "device," as that word is used in the Food, Drug, and Cosmetics Act, and is therefore subject to the full range of device regulations.

Medical apps are growing in popularity. According to The New York Times, one smart phone app, "Epocrates," is used by "nearly half of the nation's doctors" to "look up information on drug dosing, interactions and insurance coverage while seeing a patient."5 Multiple websites are devoted to reviewing and discussing medical apps, including one site that claims "400,000 views a month by the medical community." www.iMedicalApps.com

The FDA does not view all applications with medical purposes as requiring regulatory supervision. The FDA intends to "exercise its discretion to decline to pursue enforcement actions" in connection with some classes of medical applications. Applications that will not be the subject of enforcement actions include electronic versions of medical reference works, apps relating to "maintaining general health and wellness," and apps used to perform general office functions (tailored to a medical office or otherwise). The boundary line appears to reflect whether the app is marketed for a "specific medical indication," or to analyze a specific patient.

However, the FDA's stated intent to forebear will be of little comfort should the FDA change its mind. The guidance document is merely a draft. Furthermore, even a final guidance document will not excuse anyone from complying with all applicable regulations and will not bind the FDA. Therefore, all companies involved with medical mobile apps should carefully analyze whether they are selling a regulated "device."

When Is a Handheld Computer a "Device"?

When determining whether a machine is a regulated "device," the question is not whether the machine can be used for specified medical purposes, but whether the machine is "intended for" such uses. See FD&C Act, § 201(h). As applied to handheld computers, this definition results in considerable ambiguity. Some purchasers will want to use handheld computers to diagnose or treat disease, and some sellers will actively market this ability. But most consumers will not seek out medical apps, and even a medical professional is likely to use a handheld computer primarily for nonmedical purposes.

The FDA's draft guidance indicates that the status of a machine is not defined by its attributes, but by the intent of the seller. The determination of the seller's intent will often (but not always) turn on the seller's marketing claims and the accompanying labeling. For example, the draft guidance indicates that a machine will be viewed as a "device" if advertised as capable of performing medical functions. The same machine might not be a regulated device if sold without such claims. Thus sellers of handheld computers and mobile apps have some ability to control whether they are selling regulated "devices." However, a seller's intent can also be "shown by the circumstances surrounding the distribution of the article." 21 C.F.R. § 801.4 (defining "intended uses" in connection with labeling obligations). It is therefore unclear whether a seller of a handheld computer can achieve a safe harbor merely by avoiding making medical claims in its advertising and labeling.

Adding to the complexity is the fact that different actors in the supply chain may have different intentions. As a result, the FDA indicated that a machine that is not a "device" when first sold might become a regulated device if then resold—even if unchanged—by a distributor who markets the machine's potential use to aid in medical diagnosis or treatment.

Who Is the "Manufacturer" of a Mobile Medical App?

Manufacturers, as a practical matter, usually bear primary or exclusive responsibility for compliance with the full range of applicable regulations. The question of who is the "manufacturer" of a device thus bears real-world significance, and is addressed in the FDA's new draft guidance.

At present, the FDA is most focused upon those who create and control the software. Thus the primary manufacturers, at least under the FDA's current view, are the software designers and programmers. These "manufacturers" include the companies that develop the specifications for the apps and contract with others to perform the programming. Some medical apps operate by granting access to a web site that provides the application's functionality. For these apps, the "manufacturers" include the company responsible for the web site.

By contrast, the FDA does not appear to be focused upon the hardware involved (i.e., the handheld computer). A company that merely manufactures the hardware platform—without intending that it be used as (or as part of) a medical device—is currently considered by the FDA to be a mere "component manufacturer." Component manufacturers are exempt from many device regulations, including the requirements relating to registering manufacturing facilities, listing the medical devices produced, filing premarket notifications or approval applications, and observing "good manufacturing practices." 21 C.F.R. §§ 807.65(a), 807.81(a), 820.1(a).

Similarly, the draft guidance indicates that companies that solely perform a distribution function (such as enabling on-line sales of apps) are not manufacturers.

Manufacturers, however, are not the only companies that have regulatory burdens relating to medical devices. Importers often have the same duties as manufacturers.6 Even distributors must maintain incident reports and make them available to FDA inspectors upon request. 21 C.F.R. § 803.18(d)(1)-(3).

The FDA Is Soliciting Comments

FDA policy regarding software-driven medical devices has been in flux for some time. An earlier attempt at a single, overarching software policy was withdrawn as a failure in light of fast technological developments and dramatic increases in the number of software-driven devices. See 70 F.R. 824 (Jan. 5, 2005) (withdrawing "Draft Software Policy"). Given this history, and given the FDA's awareness that it is regulating a rapidly changing industry, the FDA should be receptive to comments on the new draft guidance.

Accordingly, the FDA is soliciting comments regarding its Medical Mobile Apps draft guidance. Such comments can help inform the FDA regarding who should bear the burdens connected with the device regulations, and how the burdens can be minimized.

Comments are due by October 19, 2011. 76 F.R. 43689 (July 21, 2011).


1. Draft Guidance for Industry and Food and Drug Administration Staff; Mobile Medical Applications.

2. 21 C.F.R. § 872.6390 (dental floss); § 870.1875 (stethoscopes).

3. 21 C.F.R. § 870.3610.

4. See 21 C.F.R. Parts 801, 803, 806, 807, 814, 820, 821, 822.

5. New York Times, Drug App Comes Free, Ads Included (July 28, 2011).

6. See 21 C.F.R.§§ 803.40 (adverse events reporting); 806.10(a) (reports of corrections and removals); 807.20(a)(4) (registration of manufacturing establishments); 807.81 (premarket notification); 821.4 (tracking devices after sale); 822.3(g) (postmarket surveillance).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Jonathan Berman
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions